Mucosa microcrystal bacteriostatic ointment as well as preparation method and application thereof
Through the combination of microcrystalline structure and excipients of the pure ointment system, the problems of insufficient fluidity and environmental impact of vaginal mucosal antibacterial preparations in the prior art are solved, and the uniform release of antibacterial ingredients and better efficacy are achieved, avoiding the adverse effects on mucosal environment.
Patent Information
- Application Number
- CN202411170813.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-26
AI Technical Summary
The existing vaginal mucosal antibacterial preparations have insufficient fluidity, resulting in uneven distribution and difficulty in drug release. Water-based products have an impact on the osmotic pressure and acid-base environment on the mucosal environment, resulting in poor efficacy. and swelling of cells.
Using a pure oil paste system, a microcrystalline structure containing excipients has viscosity and fluidity in vitro, and provides slow-release antibacterial components through body temperature softening, which does not affect the acid and alkaline environment of the mucosa and is lubricating so as to be Slide and discharge from secretions.
The uniform release of antibacterial components and better therapeutic effects are achieved, the adverse effects on the mucosal environment are avoided, and better adhesion and bionic barrier protection are provided, which improves the retention and efficacy of drugs.
Smart Images

Figure CN119015214A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of disinfection and hygiene products, in particular to a mucosal microcrystalline antibacterial ointment and a preparation method and application thereof. Background Art
[0002] Mucosal antibacterial preparations inhibit the growth of microorganisms and provide good help for the control of diseases in the mucosal area. Currently, most vaginal mucosal antibacterial preparations on the market are hydrogel preparations, emulsions or liquid preparations. Hydrogel preparations have poor fluidity, and the viscous material is placed in the vagina, resulting in uneven distribution. In addition, due to the hydrogel polymer network structure, the antibacterial components are difficult to release, resulting in some parts not contacting the material. Emulsions or liquid preparations have good fluidity, but it is difficult for them to stay and maintain their efficacy. At present, some liquid products are combined with gauze rolls and inserted into the body. The operation is very cumbersome, and most of the liquid is absorbed by the gauze, resulting in a large loss of medicine, and a strong foreign body sensation when used. At the same time, most water-based products affect the osmotic pressure and acid-base environment of the mucosa, causing repeated swelling and swelling of cells in the mucosal area, causing damage.
[0003] In the prior art, when antibacterial preparations are used for drug administration treatment to the mucosa, the use of hydrogel preparations, emulsions or liquid preparations will cause the viscous material to be placed in the vagina, which does not flow, resulting in uneven distribution and difficulty in release, resulting in some parts not being contacted by the material; the emulsion or liquid preparation is difficult to stay and maintain the therapeutic effect, the drug cannot effectively exert its therapeutic effect, and the water-based material affects the osmotic pressure and acid-base environment of the mucosa. Summary of the invention
[0004] The purpose of the present invention is to provide a mucosal microcrystalline antibacterial ointment to solve the problems of the prior art. The ointment has viscosity in vitro due to the presence of an excipient, and can be placed at a designated site when injected into the body. The excipient is a composite of a crystalline and amorphous substance with a melting point, and is softened by body temperature and has a certain slow fluidity, and has no high molecular weight hydrogel steric hindrance structure; at the same time, due to the microcrystalline structure, it is in a flower-like or fibrous shape, and has a certain adhesion to the mucosa, and can fully release the antibacterial components to the mucosal site to exert its effect.
[0005] The product of the present invention is a pure ointment system, does not contain water, and will not form osmotic pressure and pH impact on the mucosal environment due to its strong ionicity. At the same time, it can buffer substances that affect the osmotic pressure and acid-base environment in the mucosal environment, thereby maintaining the original physiological environment of the mucosal area; the ointment softened by body temperature can allow secretions to slide and be adsorbed due to its own lubricity compared to water-based products, thereby achieving better therapeutic effects than existing products.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] A mucosal microcrystalline antibacterial ointment, comprising an oil, an excipient, a solvent, and an antibacterial agent, wherein:
[0008] The oil agent is one or more of vegetable oil, synthetic oil, animal oil, and mineral oil;
[0009] The excipient is one or more of oleogel, beeswax, plant waxes, and synthetic wax esters;
[0010] The solvent is one or more of alcohols, fatty acids, spans, and water-oil amphiphilic polyethers;
[0011] The antibacterial agent is one or more of chlorine-containing disinfectants, biguanides, peroxides, benzalkonium bromide, and plant antibacterial agents.
[0012] Furthermore, the vegetable oil in the oil preparation contains one or more of sesame oil, camellia oil, hazelnut oil, almond oil and Andiroba oil.
[0013] Furthermore, the antibacterial agent includes chlorine-containing disinfectants such as chlorhexidine acetate or chlorhexidine gluconate, biguanides such as polyhexamethylene biguanide, peroxides such as ozone oil and benzalkonium bromide, and plant antibacterial agents such as one or more extracts of Scutellaria baicalensis, Coptis chinensis, Phellodendron amurense, Artemisia annua, and Sophora flavescens.
[0014] Furthermore, the antibacterial agent is chlorhexidine acetate.
[0015] Furthermore, in terms of mass percentage, the oil agent is 60%-96%, the excipient is 0.5%-25%, the solvent is 0.2%-10%, and the antibacterial agent is 0.1%-10%.
[0016] Furthermore, in terms of mass percentage, the camellia oil comprises 60.55%, caprylic / capric triglyceride 19%, squalane 10%, cetearyl alcohol 2.0%, beeswax 5%, pentylene glycol 2%, chlorhexidine acetate 0.25%, cymene 0.5%, phellodendron amurense extract 0.2%, and scutellaria baicalensis extract 0.5%.
[0017] A mucosal microcrystalline antibacterial ointment comprises, by mass percentage, 60.75% of sesame oil, 19% of caprylic / capric triglyceride, 10% of squalane, 2.0% of cetearyl alcohol, 5% of synthetic wax, 2% of propylene glycol, 0.25% of chlorhexidine acetate, 0.2% of phellodendron amurense extract, 0.5% of scutellaria baicalensis extract and 0.3% of pulsatilla scabra extract.
[0018] A mucosal microcrystalline antibacterial ointment comprises, by mass percentage, 51.61% of sesame oil, 19% of caprylic / capric triglyceride, 10% of squalane, 2.0% of cetearyl alcohol, 5% of beeswax, 9% of dimethyl isosorbide, 0.6% of Span 80, 2% of propylene glycol, 0.25% of chlorhexidine acetate, 0.2% of phellodendron amurense extract, 0.12% of scutellaria baicalensis extract, 0.12% of coptis root extract and 0.1% of pulsatilla scabra extract.
[0019] A method for preparing the above-mentioned mucosal microcrystalline antibacterial ointment comprises uniformly adding an excipient to an oil agent, melting and coating at 70-120°C, then uniformly cooling at 0.8-2°C / min, adding an antibacterial agent dissolved in a solvent before crystals are observed, mixing evenly by circulating flow instead of shear stirring, and slowly cooling to form a microcrystalline ointment mixed with the antibacterial agent. The mucosal microcrystalline antibacterial ointment system does not contain water, and the mucosal microcrystalline antibacterial ointment does not affect the acid-base environment of the human body.
[0020] During the preparation process of the mucosal microcrystalline antibacterial ointment of the present invention, as the temperature slowly decreases, the microcrystalline structure of the mucosal microcrystalline antibacterial ointment is gradually formed and circulated and mixed evenly to prevent the formation of excessively large crystals and prevent the formed crystals from being sheared, stirred and chopped. The viscosity of the material is controlled to be 30000-160000 mpas to control the structure of the crystals. The mixing time is greater than 30 minutes, and the length and width of the crystals are detected to be within 3*50 um. If the product is qualified, it can be canned.
[0021] The average size of the microcrystalline structure of the mucosal microcrystalline antibacterial ointment prepared by the invention is 30*0.7um.
[0022] A mucosal microcrystalline antibacterial ointment is used for the inhibition of pyogenic cocci, intestinal pathogenic bacteria, pathogenic fungi, and for the inhibition of chlamydia, mycoplasma, trichomonas, and HPV.
[0023] Beneficial effects of the present invention
[0024] Compared with the prior art, the present invention provides a mucosal microcrystalline antibacterial ointment, which has the following beneficial effects compared with the prior art:
[0025] (1) The microcrystalline structure of the mucosal microcrystalline antibacterial ointment of the present invention has a certain viscosity and fluidity, a large surface area, and is tiny and tightly arranged in layers. It can adhere to the mucosal part and flow to every corner of the mucosa at the same time, so that the drug in the ointment is fully released. The ointment has viscosity in vitro because it contains excipients, and can be placed in a designated part when injected into the body. The excipient is a composite of a crystalline and amorphous substance with a melting point, and will be softened by the body temperature and has a certain slow flow.
[0026] (2) The mucosal microcrystalline antibacterial ointment of the present invention does not contain water, so there is no strong ionization that affects the mucosal osmotic pressure and acid-base environment. At the same time, it can buffer the substances that affect the osmotic pressure and acid-base environment in the mucosal environment and drain them out of the body, thereby maintaining a healthy environment. It avoids the steric hindrance problem of conventional polymer hydrogels; at the same time, due to the microcrystalline structure, it is in a flower-like or fibrous shape and has a certain degree of adhesion to the mucosa, and can fully release the antibacterial components to the mucosal site to exert its effect.
[0027] (3) The microcrystalline antibacterial ointment of the present invention has a closely arranged microcrystalline structure, similar to the layered arrangement of cell structures, and has bionic barrier protection. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The mucosal microcrystalline antibacterial ointment of the present invention is a flower-shaped crystal under a microscope.
[0029] Figure 2 The mucosal microcrystalline antibacterial ointment of the present invention is fibrous crystals under a microscope.
[0030] Figure 3 This is the clinical trial result of Example 3 of the present invention.
[0031] Figure 4 This is a photograph of the mucosal microcrystalline antibacterial ointment of the present invention taken under a low-power microscope. DETAILED DESCRIPTION
[0032] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] By studying the antibacterial properties of various antibacterial agents, safe and efficient antibacterial agents can be screened;
[0034] The ointment was prepared with antibacterial agent, sesame oil and beeswax. The antibacterial rates of various antibacterial agents in the ointment against Staphylococcus aureus, Escherichia coli and Candida albicans were determined according to Appendix C of GB-15979-2002 to select the best antibacterial agent. The specific data of the antibacterial time of 10 minutes are as follows:
[0035] Name of antibacterial agent Staphylococcus aureus Escherichia coli Candida albicans Polyhexamethylene biguanide (0.6%) 87.13% 82.85% 63.25% Povidone-iodine (0.3%) 74.90% 65.88% 71.25% Triclosan (0.1%) 81.51% 83.19% 73.16% Chlorhexidine acetate (0.25%) 98.16% 97.37% 93.14% Benzalkonium bromide (0.1%) 86.25% 80.12% 87.32% Cymene + Paeonia suffruticosa root extract 67.18% 61.55% 80.36% Cymene + Magnolia officinalis extract 56.24% 43.21% 76.15% Triclosan 0.1% + Chlorhexidine Acetate 0.25% >99.99% >99.99% 97.24% Triclosan 0.1% + Benzalkonium Bromide 0.1% 91.03% 90.46% 89.27%
[0036] Conclusion: From the above table, we can see that the use of chlorhexidine acetate alone can achieve a broad-spectrum antibacterial effect. Although the compounding of triclosan has a certain improvement, the amount of triclosan used will produce a certain irritation. In summary, chlorhexidine acetate is selected as an antibacterial agent to be added to the system.
[0037] Example 1
[0038] A mucosal microcrystalline antibacterial ointment is prepared by selecting, by mass ratio, 60.55% of camellia oil, 19% of caprylic / capric triglyceride, 10% of squalane, 2.0% of cetearyl alcohol, 5% of beeswax, 2% of pentylene glycol, 0.25% of chlorhexidine acetate, 0.5% of cymene, 0.2% of phellodendron amurense extract, and 0.5% of scutellaria baicalensis extract.
[0039] A method for preparing a mucosal microcrystalline antibacterial ointment: dissolving all the amur cork extract, scutellaria baicalensis extract, and chlorhexidine acetate in the formula in pentylene glycol, and then mixing with caprylic / capric triglyceride according to the formula ratio at room temperature to form phase I; then fully dissolving camellia oil, squalane, cetearyl alcohol, and beeswax at 90°C to form phase II; cooling phase II to 65°C, adding phase I, and circulating and mixing evenly. To ensure the maintenance of the crystal structure of the material, the temperature is slowly circulated and cooled, the circulating cooling pipeline is wrapped with a heat-insulating sleeve to control the cooling speed, and the can is cooled to maintain the crystal structure.
[0040] Caprylic / capric triglyceride is mixed at a volume percentage of 19%, which helps to evenly disperse pentylene glycol and vegetable oils. Beeswax forms a crystalline structure with a non-crystalline structure and is mixed to form a microcrystalline structure. Cetearyl alcohol helps maintain the crystal structure with its long carbon chain. The crystal structure of beeswax and cetearyl alcohol has not yet formed at 65°C. Antibacterial agents are added and mixed evenly. The specific ratio of oil and excipient is used to control the size of microcrystals to 1um*30um. As the temperature slowly decreases, the microcrystalline structure gradually forms and the mixing is circulated evenly to prevent the formation of excessively large crystals and prevent the formed crystals from being sheared, stirred and chopped. Control the viscosity of the material to control the structure of the crystals. The mixing time can be more than 30min.
[0041] The mucosal microcrystalline antibacterial ointment prepared in Example 1 was used to act on Staphylococcus aureus, Candida albicans and Escherichia coli for more than ten minutes, and the antibacterial rate was greater than 90%.
[0042] Example 2
[0043] A mucosal microcrystalline antibacterial ointment is prepared, which comprises, by mass ratio, 60.75% of sesame oil, 19% of caprylic / capric triglyceride, 10% of squalane, 2.0% of cetearyl alcohol, 5% of synthetic wax, 2% of propylene glycol, 0.25% of chlorhexidine acetate, 0.2% of phellodendron amurense extract, 0.5% of scutellaria baicalensis extract and 0.3% of pulsatilla scabra extract.
[0044] A method for preparing a mucosal microcrystalline antibacterial ointment: dissolving all the Phellodendron chinense extract, Scutellaria baicalensis extract, Pulsatilla scabra extract, and chlorhexidine acetate in the formula in propylene glycol, and then mixing with caprylic / capric triglyceride to form phase I; then fully dissolving sesame oil, squalane, cetearyl alcohol, and synthetic wax at 90°C to form phase II; cooling phase II to 65°C, adding phase I, circulating and mixing evenly to ensure that the crystal structure of the material is maintained, slowly circulating and cooling, the circulating cooling pipeline is wrapped with an insulation cover to control the cooling speed, and canned cooling is performed to maintain the crystal structure. Control the viscosity of the material to control the structure of the crystal, and the mixing time is more than 30 minutes.
[0045] The mucosal microcrystalline antibacterial ointment prepared in Example 2 was used to act on Staphylococcus aureus, Candida albicans and Escherichia coli for more than ten minutes, and the antibacterial rate was greater than 90%.
[0046] Example 3
[0047] A mucosal microcrystalline antibacterial ointment is prepared, which comprises, by mass ratio, 51.61% of sesame oil, 19% of caprylic / capric triglyceride, 10% of squalane, 2.0% of cetearyl alcohol, 5% of beeswax, 9% of dimethyl isosorbide, 0.6% of Span 80, 2% of propylene glycol, 0.25% of chlorhexidine acetate, 0.2% of phellodendron amurense extract, 0.12% of scutellaria baicalensis extract, 0.12% of coptis chinensis extract and 0.1% of pulsatilla scabra extract.
[0048] A method for preparing a mucosal microcrystalline antibacterial ointment: dissolving all the Phellodendron chinense extract, Scutellaria baicalensis extract, Pulsatilla scabra extract, and chlorhexidine acetate in the formula in propylene glycol, and then mixing with Span 80, dimethyl isosorbide, and caprylic / capric triglyceride to form phase I; then fully dissolving sesame oil, squalane, cetearyl alcohol, and beeswax at 90°C to form phase II; cooling phase II to 65°C, adding phase I, circulating and mixing evenly to ensure that the crystal structure of the material is maintained, slowly circulating and cooling, wrapping the circulating cooling pipeline with an insulation cover to control the cooling speed, canning and cooling to maintain the crystal structure. Control the viscosity of the material to control the structure of the crystal, and the mixing time is more than 30 minutes.
[0049] It acts on Staphylococcus aureus, Candida albicans and Escherichia coli for more than ten minutes, with an inhibition rate of more than 90%.
[0050] Figure 4 This is a photograph of the mucosal microcrystalline antibacterial ointment of the present invention taken under a low-power microscope.
[0051] Test Examples 1-3 Detection Basis and Method:
[0052] 1. Test strains: Escherichia coli 8099 and Staphylococcus aureus ATCC6538 were provided by China Industrial Microbiological Culture Collection Administration Center, 4th to 8th generation fresh slant cultures; Candida albicans ATCC10231 was provided by China Industrial Microbiological Culture Collection Administration Center, 5th to 6th generation fresh slant cultures.
[0053] 2. Instruments and equipment: biological safety cabinet HFsafe-1200LC (201738JNJ035); constant temperature culture room TBG-12P-A (TSD-20200601); low temperature constant temperature water bath (202038JDJ070).
[0054] 3. Methods
[0055] 3.1.Testing basis: Appendix C of GB15979-2002 Hygiene Standard for Disposable Sanitary Products.
[0056] 3.2 Test conditions: Test temperature 19-21℃, test repeated 3 times.
[0057] 3.3 Experimental samples: Example 1 Mucosal Antibacterial Cream 1, Example 2 Mucosal Antibacterial Cream 2, Example
[0058] 3 Mucosal antibacterial cream 3
[0059] 4. Example 1 Results
[0060] 4.1 After three repeated tests, the results showed that the test sample had an effect on Escherichia coli for 2 minutes, 5 minutes, 10 minutes,
[0061] The average values of the inhibition rates at 20 minutes were 95.7%, 97.5%, >99.9%, and >99.9%, respectively. See Table 1.
[0062] Table 1. Antibacterial effect of mucosal antibacterial cream 1 on Escherichia coli
[0063]
[0064] 4.2 After three repeated tests, the results showed that the average antibacterial rates of the test sample against Staphylococcus aureus at 2min, 5min, 10min and 20min were all >99.9%. See Table 2.
[0065] Table 2. Antibacterial effect of mucosal antibacterial cream 1 on Staphylococcus aureus
[0066]
[0067]
[0068] 4.3 After three repeated tests, the results showed that the average antibacterial rates of the test sample against Candida albicans at 2min, 5min, 10min and 20min were 95.9%, 99.0%, >99.9% and >99.9% respectively. See Table 3.
[0069] Table 3. Antibacterial effect of mucosal antibacterial cream 1 on Candida albicans
[0070]
[0071] 4.4 Conclusion of Example 1
[0072] After three repeated tests, the results showed that the test sample had a strong antibacterial effect on Escherichia coli, Staphylococcus aureus and Candida albicans, and met the requirements of GB15979-2002 "Hygiene Standards for Disposable Sanitary Products".
[0073] 5. Results of Example 2
[0074] 5.1 After three repeated tests, the results showed that the test sample had an effect on Escherichia coli for 2 minutes, 5 minutes, 10 minutes,
[0075] The average values of the inhibition rates at 20 min were 92.3%, >99.9%, >99.9%, and >99.9%, respectively. See Table 4.
[0076] Table 4. Antibacterial effect of mucosal antibacterial cream 2 on Escherichia coli
[0077]
[0078] 5.2 After three repeated tests, the results showed that the average antibacterial rates of the test sample against Staphylococcus aureus at 2min, 5min, 10min and 20min were 94.0%, >99.9%, >99.9% and >99.9% respectively. See Table 5.
[0079] Table 5. Antibacterial effect of mucosal antibacterial cream 2 on Staphylococcus aureus
[0080]
[0081] 5.3 After three repeated tests, the results showed that the average inhibition rates of the test sample against Candida albicans at 2min, 5min, 10min and 20min were 57.7%, 95.4%, >99.9% and >99.9% respectively. See Table 6.
[0082] Table 6. Antibacterial effect of mucosal antibacterial cream 2 on Candida albicans
[0083]
[0084] 5.4 Test conclusion of Example 2
[0085] After three repeated tests, the results showed that the mucosal antibacterial ointment has a strong antibacterial effect on Escherichia coli and Staphylococcus aureus, and has an antibacterial effect on Candida albicans for 2 minutes, and has a strong antibacterial effect for 5 minutes, 10 minutes, and 20 minutes, which meets the requirements of GB15979-2002 "Hygiene Standards for Disposable Sanitary Products".
[0086] 6. Example 3 Results:
[0087] 6.1 After three repeated tests, the results showed that the average inhibition rates of the test sample on Escherichia coli for 2min, 5min, 10min and 20min were 85.8%, 98.5%, >99.9% and >99.9% respectively. See Table 7.
[0088] Table 7. Antibacterial effect of mucosal antibacterial cream 3 on Escherichia coli
[0089]
[0090] 6.2 After three repeated tests, the results showed that the antibacterial rates of the test sample against Staphylococcus aureus at 2min, 5min, 10min and 20min were all >99.9%. See Table 8.
[0091] Table 8. Antibacterial effect of mucosal antibacterial cream 3 on Staphylococcus aureus
[0092]
[0093] 6.3 After three repeated tests, the results showed that the average antibacterial rates of the test sample against Candida albicans at 2min, 5min, 10min and 20min were 93.2%, 97.5%, >99.9% and >99.9% respectively. See Table 9.
[0094] Table 9. Antibacterial effect of mucosal antibacterial cream 3 on Candida albicans
[0095]
[0096] 6.4 Conclusion of the test of Example 3: After three repeated tests, the results showed that the mucosal antibacterial ointment 3 had an antibacterial effect on Escherichia coli for 2 minutes, and had a strong antibacterial effect for 5 minutes, 10 minutes, and 20 minutes. It also had a strong antibacterial effect on Staphylococcus aureus and Candida albicans, which met the requirements of GB15979-2002 "Hygiene Standards for Disposable Sanitary Products".
[0097] 6.5 Clinical Experimental Results of Example 3
[0098] After using the mucosal antibacterial cream once a day at night for 5 days, the viscous secretions in the vagina are discharged in large quantities, such as Figure 3 .
Claims
1. A mucosal microcrystalline antibacterial ointment, characterized in that: Including oil, excipient, solvent, antibacterial agent, among which: The oil agent is one or more of vegetable oil, synthetic oil, animal oil, and mineral oil; The excipient is one or more of oleogel, beeswax, plant waxes, and synthetic wax esters; The solvent is one or more of alcohols, fatty acids, spans, and water-oil amphiphilic polyethers; The antibacterial agent is one or more of chlorine-containing disinfectants, biguanides, peroxides, benzalkonium bromide, and plant antibacterial agents.
2. A mucosal microcrystalline antibacterial ointment according to claim 1, characterized in that, The vegetable oil in the oil preparation includes one or more of sesame oil, tea seed oil, hazelnut oil, almond oil and Andiroba oil.
3. A mucosal microcrystalline antibacterial ointment according to claim 1, characterized in that, The antibacterial agent includes chlorine-containing disinfectants such as chlorhexidine acetate or chlorhexidine gluconate, biguanides such as polyhexamethylene biguanide, peroxides such as ozone oil and benzalkonium bromide, and plant antibacterial agents such as one or more extracts from scutellaria baicalensis, coptis chinensis, phellodendron amurense, artemisia annua, and sophora flavescens.
4. A mucosal microcrystalline antibacterial ointment according to any one of claims 1, 2 or 3, characterized in that: The antibacterial agent is chlorhexidine acetate.
5. A mucosal microcrystalline antibacterial ointment according to claim 1, characterized in that, In terms of mass percentage, the oil agent accounts for 60%-96%, the excipient accounts for 0.5%-25%, the solvent accounts for 0.2%-10%, and the antibacterial agent accounts for 0.1%-10%.
6. A mucosal microcrystalline antibacterial ointment according to claim 1, characterized in that: In terms of mass percentage, the camellia oil comprises 60.55%, caprylic / capric triglyceride 19%, squalane 10%, cetearyl alcohol 2.0%, beeswax 5%, pentylene glycol 2%, chlorhexidine acetate 0.25%, cymene 0.5%, phellodendron amurense extract 0.2%, and scutellaria baicalensis extract 0.5%.
7. A mucosal microcrystalline antibacterial ointment according to claim 1, characterized in that: In terms of mass percentage, the sesame oil comprises 60.75%, caprylic / capric triglyceride 19%, squalane 10%, cetearyl alcohol 2.0%, synthetic wax 5%, propylene glycol 2%, chlorhexidine acetate 0.25%, phellodendron amurense extract 0.2%, scutellaria baicalensis extract 0.5% and pulsatilla scabra extract 0.3%.
8. A mucosal microcrystalline antibacterial ointment according to claim 1, characterized in that: In terms of mass percentage, it contains 51.61% sesame oil, 19% caprylic / capric triglyceride, 10% squalane, 2.0% cetearyl alcohol, 5% beeswax, 9% dimethyl isosorbide, 0.6% Span 80, 2% propylene glycol, 0.25% chlorhexidine acetate, 0.2% phellodendron chinense extract, 0.12% scutellaria baicalensis extract, 0.12% coptis root extract and 0.1% pulsatilla leaf extract.
9. A method for preparing the mucosal microcrystalline antibacterial ointment according to any one of claims 1 to 8, characterized in that: The method comprises adding the excipient into the oil at a uniform speed, melting and coating at 70-120°C, then cooling at a uniform speed of 0.8-2°C / min, adding the antibacterial agent dissolved in a solvent before the formation of crystals, mixing evenly by circulating flow instead of shear stirring, and slowly cooling to form a microcrystalline ointment mixed with the antibacterial agent.
10. The method for preparing a mucosal microcrystalline antibacterial ointment according to claim 9, characterized in that: The mucosal microcrystalline antibacterial ointment system does not contain water, and the mucosal microcrystalline antibacterial ointment does not affect the acid-base environment of the human body.
11. The method for preparing a mucosal microcrystalline antibacterial ointment according to claim 10, characterized in that: As the temperature slowly decreases, the microcrystalline structure of the mucosal microcrystalline antibacterial ointment is gradually formed and mixed evenly in a circulation manner to prevent the formation of excessively large crystals and the formed crystals from being sheared, stirred and chopped, and to control the viscosity of the material to control the structure of the crystals. The mixing time can be greater than 30 minutes.
12. The method for preparing a mucosal microcrystalline antibacterial ointment according to claim 11, characterized in that: When the average size of the crystal structure is 30*0.7 um, the mixing reaction is stopped.
13. The method for preparing a mucosal microcrystalline antibacterial ointment according to claim 12, characterized in that: The material viscosity is controlled to be 30000mpas-160000mpas.
14. A mucosal microcrystalline antibacterial ointment for its antibacterial application in pyogenic cocci, intestinal pathogenic bacteria, pathogenic fungi, and its inhibitory application in chlamydia, mycoplasma, trichomonas, and HPV.
